|Mr. Gary R. Maharaj||Chief Exec. Officer, Pres and Director||918.78k||2.3M||54|
|Mr. Andrew D. C. LaFrence CPA||CFO, Principal Accounting Officer and VP of Fin. & Information Systems||444.55k||N/A||54|
|Mr. Bryan K. Phillips||Sr. VP of Legal & HR, Gen. Counsel and Corp. Sec.||493.53k||44.85k||46|
|Mr. Charles W. Olson||Sr. VP of Commercial and Bus. Devel. for Medical Devices||468.86k||649.87k||53|
|Mr. Joseph J. Stich||VP and Gen. Mang. of In-Vitro Diagnostics||421.13k||667.07k||52|
Surmodics, Inc., together with its subsidiaries, provides surface modification and in vitro diagnostic technologies to the healthcare industry worldwide. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. This segment also engages in the contract research, development, and manufacture of percutaneous transluminal angioplasty balloon catheters for use in various interventional cardiology, peripheral, and other applications. The Vitro Diagnostics segment provides component products and technologies that include protein stabilization reagents, substrates, antigens, and surface coatings for diagnostic immunoassay and molecular tests, as well as to the diagnostic, biomedical research, and life science markets. SurModics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Surmodics, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 5. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 6; Compensation: 2.